Kyverna Therapeutics, Inc.
Kyverna Therapeutics, Inc. scores highest on Anchor (41) and lowest on Earnings (22). Its PosiPenta is 30.87 out of 100, weaker than most similar companies.
On the Penta Grid this week, Kyverna Therapeutics, Inc. is Grid #749 of 836 in the Healthcare sector in United States, and Grid #3,569 of 3,999 in United States.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| Kyverna Therapeutics, Inc. | 30.87 | 28 | 22 | 26 | 38 | 41 |
| Orchestra BioMed Holdings, Inc. | 38.47 | 4 | 31 | 84 | 8 | 66 |
| Enanta Pharmaceuticals, Inc. | 35.04 | 21 | 26 | 54 | 25 | 50 |
| Atea Pharmaceuticals, Inc. | 52.51 | 31 | 37 | 68 | 63 | 64 |
| Capricor Therapeutics, Inc. | 38.82 | 33 | 39 | 27 | 36 | 60 |
| Zura Bio Limited | 52.38 | 30 | 47 | 47 | 68 | 69 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -1.94 |
| P/B ratio | 2.12 |
EEarnings
| Trailing EPS | ₹-277.51 |
| Forward EPS | ₹-300.17 |
NNitro
| Price | 537.03 |
| 52-week high | 1294.75 |
| 52-week low | 531.35 |
| Fall from 52-week high | 58.5% |
TTorque
| Return on equity (ROE) | -87.24% |
| Debt-to-equity | 0.20 |
AAnchor
| Beta (price swings) | 2.06 |
| Market cap | ₹3,321 Cr |
| Insider holding | 6.98% |
| Dividend yield | 0.00% |
Figures as used for the week of 17 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is Kyverna Therapeutics, Inc.'s PosiPenta score?
Kyverna Therapeutics, Inc.'s PosiPenta is 30.87 out of 100 for the week of 17 Oct 2026, based on 5 of 5 pillars.
Where does Kyverna Therapeutics, Inc. stand on the Penta Grid?
On the Penta Grid this week, Kyverna Therapeutics, Inc. is Grid #749 of 836 in the Healthcare sector in United States, and Grid #3,569 of 3,999 in United States.
Which PosiPenta pillar is strongest for Kyverna Therapeutics, Inc.?
Anchor (stability and dividends), with a score of 41 out of 100: around the middle of similar companies.
Which PosiPenta pillar is weakest for Kyverna Therapeutics, Inc.?
Earnings (growth), with a score of 22 out of 100: weaker than most similar companies.
Has Kyverna Therapeutics, Inc.'s PosiPenta changed since last week?
Yes, it rose 3.20 points, from 27.67 to 30.87.
PositoAI is for research and education only and is not investment advice.